US FDA Won't Budge On Nitrosamines Compliance Despite Complaints Of Possible Drug Shortages

Chemcial diagram of probable carcinogen N-nitrosodimethylamine linked to FDA's investigation of nitrosamines in drugs that began after an independent testing firm in 2019 submitted petition showing it in OTC heartburn remedies with ranitidine as an active ingredient. • Source: Alamy

More from Ingredients & Safety

More from HBW Insight